FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study

摘要: Objective To evaluate the efficacy and toxicity profile of combination fludarabine, high dose cytarabine, idarubicin, granulocyte colony stimulating factor in refractory relapsed cases acute leukaemia, a study is being conducted at Armed Forces Bone Marrow Transplant Centre (AFBMTC) Rawalpindi since January 2003. Data up to June 2004 (early report) presented. Methods Twelve Patients with refractory/relapsed (Ref/Rel) leukaemia (AL) were treated fludarabine 30 mg/m2 cytosine arabinoside (AraC) Arac 2 g/m2 for 5 days, idarubicin 10 3 G-CSF micro g/kg from day 0 till neutrophil recovery (ANC > 1.0 x 10(9)/1). Response was evaluated by bone marrow examination on 20-post chemotherapy. Results included lymphoblastic (ALL) (n=2), ALL (n = 3), myeloid (AML) secondary AML (n=2) 1) undifferentiated (AUL) 1). Complete remission (CR) achieved 8 (66.6%) patients. Three (25%) patients died post chemotherapy complications one patient failed achieve remission. Out who CR, 4 underwent allogeneic transfusion (BMT), 1 same, received idorubicin, AraC etopuside (ICE) AraC, did not receive further two months after Seven are still CR median follow (range 3-18). Major encountered diarrhoea, mucositis, toxic ileus, transient hepatic toxicity, fungal bacterial infections. Conclusion In our experience, FLAG-IDA well tolerated effective regimen relapsed/refractory leukaemias. The acceptable, enabling most treatment, including transplantation procedures.